Zebrafish offer the potential for a primary screen to identify a wide variety of potential anticonvulsants

Epilepsy Research

Volumn 75, Issue 1, 2007, Pages 18-28

  Berghmans, Stephane ^a   Hunt, Julia ^a   Roach, Alan ^a   Goldsmith, Paul ^a,b  

^a VASTox plc   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

AEDs; Epilepsy; Pentylene tetrazole; Screen; Zebrafish

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIAZEPAM; DIMETHYL SULFOXIDE; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PENTETRAZOLE; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT THERAPY; ARTICLE; BODY MOVEMENT; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESEARCH; DRUG SCREENING; EMBRYO; EPILEPSY; EXPERIMENTAL MODEL; FISH; HIGH THROUGHPUT SCREENING; LARVA; LOCOMOTION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SEDATION; TOXICITY TESTING; ZEBRA FISH;

ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; EMBRYO, NONMAMMALIAN; EPILEPSY; MOVEMENT; PENTYLENETETRAZOLE; TIME FACTORS; ZEBRAFISH;

EID: 34249813382     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2007.03.015     Document Type: Article

References (24)

1. Baraban S.C., Taylor M.R., Castro P.A., and Baier H. Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. Neuroscience 131 (2005) 759-768
2. Berghmans S., Jette C., Langenau D., Hsu K., Stewart R., Look T., et al. Making waves in cancer research: new models in the zebrafish. Biotechniques 39 (2005) 227-237
3. Detrich III H.W., Westerfield M., and Zon L.I. Overview of the zebrafish system. Methods Cell Biol. 59 (1999) 3-10
4. Driever W., Solnica-Krezel L., Schier A.F., Neuhauss S.C., Malicki J., Stemple D.L., et al. A genetic screen for mutations affecting embryogenesis in zebrafish. Development 123 (1996) 37-46
5. Fisher R.S. Animal models of the epilepsies. Brain Res. Brain Res. Rev. 14 (1989) 245-278
6. Goldsmith P. Zebrafish as a pharmacological tool: the how, why and when. Curr. Opin. Pharmacol. 4 (2004) 504-5012
7. Kimmel C.B., Ballard W.W., Kimmel S.R., Ullmann B., and Schilling T.F. Stages of embryonic development of the zebrafish. Dev. Dyn. 203 (1995) 253-310
8. Langheinrich U. Zebrafish: a new model on the pharmaceutical catwalk. Bioessays 25 (2003) 904-912
9. Loscher W. Genetic animal models of epilepsy as a unique resource for the evaluation of anticonvulsant drugs. A review. Methods Find. Exp. Clin. Pharmacol. 6 (1984) 531-547
10. Merritt H.H., and Putnam T.J. Landmark article September 17, 1938: sodium diphenyl hydantoinate in the treatment of convulsive disorders. By H. Houston Merritt and Tracy J. Putnam. JAMA 251 (1984) 1062-1067
11. Mody I., and Schwartzkroin P. Acute seizure models (intact animals). In: Engel J., and Pedley T.A. (Eds). Epilepsy: A Comprehensive Textbook (1998), Lippincott-Raven, Philadelphia 397-404
12. Ninkovic J., and Bally-Cuif L. The zebrafish as a model system for assessing the reinforcing properties of drugs of abuse. Methods 39 (2006) 262-274
13. Olsen R.W. The GABA postsynaptic membrane receptor-ionophore complex. Site of action of convulsant and anticonvulsant drugs. Mol. Cell. Biochem. 39 (1981) 261-279
14. Peterson R.T., and Fishman M.C. Discovery and use of small molecules for probing biological processes in zebrafish. Methods Cell Biol. 76 (2004) 569-591
15. Shafizadeh E., and Paw B.H. Zebrafish as a model of human hematologic disorders. Curr. Opin. Hematol. 11 (2004) 255-261
16. Stables J.P., Bertram E.H., White H.S., Coulter D.A., Dichter M.A., Jacobs M.P., et al. Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland. Epilepsia 43 (2002) 1410-1420
17. Stern H.M., Murphey R.D., Shepard J.L., Amatruda J.F., Straub C.T., Pfaff K.L., et al. Small molecules that delay S phase suppress a zebrafish bmyb mutant. Nat. Chem. Biol. 1 (2005) 366-370
18. Stilwell G.E., Saraswati S., Littleton J.T., and Chouinard S.W. Development of a drosophila seizure model for in vivo high-throughput drug screening. Eur. J. Neurosci. 24 (2006) 2211-2222
19. Sumanas S., and Larson J.D. Morpholino phosphorodiamidate oligonucleotides in zebrafish: a recipe for functional genomics?. Brief Funct. Genomic Proteomic 1 (2002) 239-256
20. Swinyard E.A., Brown W.C., and Goodman L.S. Comparative assays of antiepileptic drugs in mice and rats. J. Pharmacol. Exp. Ther. 106 (1952) 319-330
21. Swinyard E.A., and Kupferberg H.J. Antiepileptic drugs: detection, quantification, and evaluation. Fed. Proc. 44 (1985) 2629-2633
22. Wallace K.N., and Pack M. Unique and conserved aspects of gut development in zebrafish. Dev. Biol. 255 (2003) 12-29
23. Westerfield M., Doerry E., Kirkpatrick A.E., Driever W., and Douglas S.A. An on-line database for zebrafish development and genetics research. Semin. Cell Dev. Biol. 8 (1997) 477-488
24. Zon L.I., and Peterson R.T. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 4 (2005) 35-44